Antithrombotic therapy with low molecular weight heparin in children

Basit Öğe Kaydı
dc.authorscopusid6603797505
dc.contributor.authorYi?it, Hakan
dc.date.accessioned2024-09-19T15:49:49Z
dc.date.available2024-09-19T15:49:49Z
dc.date.issued2003
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractThe incidence of thromboembolic events in children has significantly increased in the last decade, mainly because the thromboembolic events are becoming the most common complications of the increasingly higher incidence of tertiary care managements for serious primary disorders of childhood. The current standard antithrombotic therapy in children consists of initial short-term intravenous administration of unfractionated heparin, followed by long-term oral anticoagulants. Both these drugs have several disadvantages which limit optimal treatment and prevention of thromboembolic events in children. During the last two decades, results of several large randomised clinical trials have demonstrated important specific advantages of low molecular weight heparin over unfractionated heparin for the prevention and treatment of thromboembolic events in adults. Compared to standard heparin low molecular weight heparins have superior bioavailability, a longer half life, and a dose-independent clearance, which result in a more predictable anticoagulant response. Low molecular weight heparins are administrated subcutaneously and require minimal laboratory monitoring and dose adjustment, and thus offering important benefits to children with poor venous access. Based on the available data, low molecular weight heparins seem to be an efficient and safe alternative to standard anticoagulation therapy with unfractionated heparin and oral anticoagulants.en_US
dc.identifier.endpage94en_US
dc.identifier.issn1016-5134
dc.identifier.issue12en_US
dc.identifier.scopus2-s2.0-1242286020en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage90en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12483/15435
dc.identifier.volume15en_US
dc.indekslendigikaynakScopusen_US
dc.language.isotren_US
dc.relation.ispartofSENDROMen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectanticoagulant agenten_US
dc.subjectheparinen_US
dc.subjectlow molecular weight heparinen_US
dc.subjectanticoagulationen_US
dc.subjectchilden_US
dc.subjectchildhood diseaseen_US
dc.subjectdose responseen_US
dc.subjectdrug bioavailabilityen_US
dc.subjectdrug clearanceen_US
dc.subjectdrug efficacyen_US
dc.subjectdrug half lifeen_US
dc.subjecthumanen_US
dc.subjectreviewen_US
dc.subjectthromboembolismen_US
dc.subjectvascular accessen_US
dc.titleAntithrombotic therapy with low molecular weight heparin in childrenen_US
dc.title.alternativeÇocukluk ça?inda düşük molekül a?irlikli heparinlerin kullanimien_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu